Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Current Assets: 2010-2024

Historic Current Assets for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Dec 2024 value amounting to $51.0 million.

  • Lineage Cell Therapeutics' Current Assets rose 22.85% to $42.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.3 million, marking a year-over-year increase of 22.85%. This contributed to the annual value of $51.0 million for FY2024, which is 32.66% up from last year.
  • As of FY2024, Lineage Cell Therapeutics' Current Assets stood at $51.0 million, which was up 32.66% from $38.4 million recorded in FY2023.
  • Lineage Cell Therapeutics' 5-year Current Assets high stood at $111.5 million for FY2021, and its period low was $38.4 million during FY2023.
  • Over the past 3 years, Lineage Cell Therapeutics' median Current Assets value was $51.0 million (recorded in 2024), while the average stood at $49.8 million.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Current Assets soared by 153.53% in 2021 and then crashed by 46.21% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Current Assets (Yearly) stood at $44.0 million in 2020, then spiked by 153.53% to $111.5 million in 2021, then tumbled by 46.21% to $60.0 million in 2022, then tumbled by 35.93% to $38.4 million in 2023, then surged by 32.66% to $51.0 million in 2024.